{
  "info": {
    "company_name": "Galapagos NV",
    "company_url": "https://www.responsibilityreports.com/Company/galapagos-nv",
    "ticker_name": "GLPG",
    "exchange": "NASDAQ",
    "industry": "Biotechnology",
    "sector": "Healthcare",
    "about_company": "Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Galapagos\u2019 pipeline comprises Phase 3 through to discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. Their target discovery platform has delivered three novel mechanisms\u2026More",
    "num_employees": "501-1000 Employees",
    "location": "Based in Mechelen, Belgium"
  },
  "reports": [
    {
      "pdf_url": "https://www.responsibilityreports.com/HostedData/ResponsibilityReportArchive/g/NASDAQ_GLPG_2019.pdf",
      "report_name": "NASDAQ_GLPG_2019"
    },
    {
      "pdf_url": "https://www.responsibilityreports.com/HostedData/ResponsibilityReportArchive/g/NASDAQ_GLPG_2020.pdf",
      "report_name": "NASDAQ_GLPG_2020"
    },
    {
      "pdf_url": "https://www.responsibilityreports.com/HostedData/ResponsibilityReports/PDF/NASDAQ_GLPG_2021.pdf",
      "report_name": "NASDAQ_GLPG_2021"
    }
  ]
}